From Yahoo Finance: 2025-05-11 17:14:00

President Trump’s healthcare executive order directed collaboration with Congress to revamp Medicare’s prescription drug price negotiation law, a win for the sector. Drug makers aim to delay small-molecule drug eligibility for Medicare negotiations by four years, with a 13-year wait for biotech drugs. The order also targets cutting healthcare costs.

Medicare’s negotiation powers have sparked debate, with drug makers criticizing the timeline for negotiation eligibility. White House officials suggest potential savings from changes to the negotiation process surpass those achieved under the Biden administration. Alignment Healthcare, Inc. (ALHC) ranks as the 11th best-performing healthcare stock, with bullish investor sentiment and positive financials.

Alignment Healthcare, Inc. (ALHC) reported a 47.5% revenue increase in fiscal Q1 2025, with a 31.7% rise in Medicare Advantage membership. The company surpassed guidance on key performance indicators and expects adjusted EBITDA between $10 million and $18 million in fiscal Q2 2025. ALHC ranks 11th on the list of best performing healthcare stocks.

Read more: Is Alignment Healthcare (ALHC) the Best Performing Healthcare Stock to Buy Now?